Patents by Inventor Chao-Wei Liao
Chao-Wei Liao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10400013Abstract: A fusion polypeptide is disclosed, which includes: (a) a mucosa targeting polypeptide; (b) a translocating peptide for translocation; and (c) a antigenic epitope. In addition, a method for enhancing a stimulation of an immune response using the aforementioned fusion polypeptide is also disclosed.Type: GrantFiled: October 26, 2017Date of Patent: September 3, 2019Inventors: Chao-Wei Liao, Chung-Chin Chen
-
Publication number: 20180111964Abstract: A fusion polypeptide is disclosed, which includes: (a) a mucosa targeting polypeptide; (b) a translocating peptide for translocation; and (c) a antigenic epitope. In addition, a method for enhancing a stimulation of an immune response using the aforementioned fusion polypeptide is also disclosed.Type: ApplicationFiled: October 26, 2017Publication date: April 26, 2018Inventors: Chao-Wei LIAO, Chung-Chin CHEN
-
Publication number: 20140203462Abstract: A method of manufacturing a plate workpiece with surface microstructures is provided. Before press-molding, a preform is placed between a first mold with a pattern and a second mold, and is disposed on the second mold. Next, the first mold and the second mold are heated to a transition temperature of the preform, and then pressed against the preform to impress the pattern onto the preform to obtain a patterned preform. Finally, the patterned preform is cooled with the second mold and shrunk to obtain the plate workpiece with surface microstructures. Since the patterned preform is uniformly cooled from bottom to top by thermal conduction, the temperature field is isothermal in a horizontal distribution. Therefore, a plate workpiece with high accuracy surface microstructures is obtained, and is useful for carrying multiple optical fibers in optical communication.Type: ApplicationFiled: January 22, 2013Publication date: July 24, 2014Applicant: CHAO-WEI METAL INDUSTRIAL CO. LTDInventors: Yung-Yuan Liao, Chao-Wei Liao
-
Patent number: 8372407Abstract: A method for inducing HIV antigen-specific immune responses is disclosed. The method comprises administering to a subject in need thereof a therapeutically effective amount of a chimeric fusion protein comprising: (a) a first polypeptidyl region comprising a Pseudomonas Exotoxin A (PE) binding domain and a PE translocation domain, located at the N-terminus of the fusion protein; and (b) a second polypeptidyl region with a fusion peptide of HIV gp120-C1-C5-gp41 with the amino acid sequence of SEQ ID NO: 7. A method for inducing neutralizing antibodies against HIV-1 is also disclosed.Type: GrantFiled: April 20, 2012Date of Patent: February 12, 2013Assignee: TheVax Genetics Vaccine Co., Ltd.Inventors: Chao-Wei Liao, Hsiu-Kang Chang
-
Publication number: 20120213811Abstract: A method for treating HIV infection is disclosed. The method comprises administering to a patient in need thereof a therapeutically effective amount of a fusion protein comprising: a) a Pseudomonas Exotoxin A (PE) peptide comprising a binding domain and a PE translocation domain, the PE peptide being devoid of cytotoxic domain III; b) optionally gag24, being fused to the PE peptide; c) a fragment of gp120 C1 domain, being fused to the PE peptide or fused to the gag24 if the gag24 is present; d) a fragment of gp 120 C5 domain, being fused to the fragment of gp120 C1 domain; e) a fragment of gp41 amino acid sequence, being fused to the fragment of gp 120 C5 domain, and f) optionally an endoplasmic reticulum retention sequence, being fused to the C-terminus of the fragment of gp41.Type: ApplicationFiled: April 20, 2012Publication date: August 23, 2012Applicants: HEALTHBANKS USA INC., HEALTHBANKS BIOTECH CO., LTD.Inventors: CHAO-WEI LIAO, HSIU-KANG CHANG
-
Patent number: 8206950Abstract: Fusion antigen used as vaccine and method of making them. The method includes: (1) selecting a segment of a virus protein sequence that contains a least one epitope; (2) engineering a DNA fragment encoding the selected segment of the virus protein; (3) inserting the DNA fragment into a Pseudomonas Exotoxin A (PE) vector to obtain a chimeric gene plasmid, and expressing the chimeric gene plasmid in a host cell to obtain the chimeric vaccinal virus antigen. The PE vector contains a PE fragment, which has a binding domain and a translocating domain, and a carboxyl terminal moiety, which includes an endoplasmic reticulum retention sequence. The DNA fragment encoding the selected segment of the virus protein is inserted between the PE fragment and the carboxyl terminal moiety.Type: GrantFiled: November 22, 2008Date of Patent: June 26, 2012Assignee: Animal Technology Institute TaiwanInventors: Chao-Wei Liao, Chung-Nan Weng, Hsiu-Kang Chang
-
Patent number: 7595054Abstract: Fusion antigen used as vaccine. The invention relates to a fusion antigen specific for a target cell. The fusion antigen contains a ligand moiety, a Pseudomonas exotoxin A translocation domain II, an antigenic moiety, and a carboxyl terminal moiety. The ligand moiety is capable of reacting, recognizing or binding to receptors on the target cell. The carboxyl terminal moiety permits retention and processing of the fusion antigen in the endoplasmic reticulum (ER) membrane of the target cell. Pharmaceutical compositions and methods of inducing an immune response using the same are also disclosed.Type: GrantFiled: November 30, 2007Date of Patent: September 29, 2009Assignee: Healthbanks Biotech Co., Ltd.Inventors: Chao-Wei Liao, Chung-Nan Weng, Hsiu-Kang Chang
-
Publication number: 20090203884Abstract: A chimeric fusion protein useful as an immunogen for inducing HIV antigen-specific immune responses contains a first polypeptidyl region and a second polypeptidyl region. The first polypeptidyl region includes a Pseudomonas Exotoxin A (PE) binding domain and a PE translocation domain. The second polypeptidyl region includes (i) a first peptidyl segment containing a fragment of gp120 C1 domain, located at the N-terminus of the second peptidyl region; (ii) a second peptidyl segment containing a fragment of gp120 C5 domain, located at the C-terminus of the first peptidyl segment; and (iii) a third peptidyl segment containing a fragment of gp41, located at the C-terminus of the second peptidyl segment. The second polypeptidyl region contains an antigenic determinant specific to one subtype of HIV. An intermediate polypeptide containing a non-Env, HIV antigenic determinant selected from Gag24, Nef, Tat and Rev may be included.Type: ApplicationFiled: January 23, 2009Publication date: August 13, 2009Applicants: HealthBanks Biotech Co., Ltd., HealthBanks USA Inc.Inventors: Chao-Wei LIAO, Hsiu-Kang Chang
-
Publication number: 20090088556Abstract: Fusion antigen used as vaccine and method of making them. The method includes: (1) selecting a segment of a virus protein sequence that contains a least one epitope; (2) engineering a DNA fragment encoding the selected segment of the virus protein; (3) inserting the DNA fragment into a Pseudomonas Exotoxin A (PE) vector to obtain a chimeric gene plasmid, and expressing the chimeric gene plasmid in a host cell to obtain the chimeric vaccinal virus antigen. The PE vector contains a PE fragment, which has a binding domain and a translocating domain, and a carboxyl terminal moiety, which includes an endoplasmic reticulum retention sequence. The DNA fragment encoding the selected segment of the virus protein is inserted between the PE fragment and the carboxyl terminal moiety.Type: ApplicationFiled: November 22, 2008Publication date: April 2, 2009Applicant: HEALTHBANKS BIOTECH CO., LTD.Inventors: Chao-Wei LIAO, Hsiu-Kang CHANG, KinKai HWANG
-
Publication number: 20090061488Abstract: The present invention provides a method of synthesizing a target polynucleotide encoding a protein, which uses a primer extension technique to constitute the target polynucleotide sequence. Preferably, the method is applied in a method for highly expressing a protein encoded by the target polynucleotide in a host.Type: ApplicationFiled: April 27, 2007Publication date: March 5, 2009Inventors: Chao-Wei Liao, Shin-Hung Lin, Chi-Min Chen, Chung-Nan Weng
-
Patent number: 7465455Abstract: A fusion protein of porcine reproductive and respiratory syndrome virus (PRRSV) for PRRSV vaccine. The fusion protein includes: (a) a Pseudomoitas Exoloxin A (PE) peptide that comprises a binding domain and a translocating domain; (b) a peptide fragment that contains a N-terminal portion of PRRSV ORF6 protein; (c) a peptide fragment that has a N-terminal portion of PRRSV ORF5 protein; and (d) a carboxyl terminal domain that comprises an amino acid seciuence KDEL. The PE peptide is located at the N-terminus of the fusion protein, and the peptide fraament containinC the N-terminal portion of PRRSV ORF5 protein is located between the peptide fragment containing the N-terminal portion of PRRSV ORF6 protein and the carboxyl terminal domain.Type: GrantFiled: July 5, 2006Date of Patent: December 16, 2008Assignee: Healthbanks Biotech Co., Ltd.Inventors: Hsiu-Kang Chang, Chao-Wei Liao
-
Publication number: 20080206271Abstract: Fusion antigen used as vaccine. The invention relates to a fusion antigen specific for a target cell. The fusion antigen contains a ligand moiety, a Pseudomonas exotoxin A translocation domain II, an antigenic moiety, and a carboxyl terminal moiety. The ligand moiety is capable of reacting, recognizing or binding to receptors on the target cell. The carboxyl terminal moiety permits retention and processing of the fusion antigen in the endoplasmic reticulum (ER) membrane of the target cell. Pharmaceutical compositions and methods of inducing an immune response using the same are also disclosed.Type: ApplicationFiled: November 30, 2007Publication date: August 28, 2008Applicants: HEALTHBANKS BIOTECH Co., Ltd., ANIMAL TECHNOLOGY INSTITUTE TAIWANInventors: Chao-Wei Liao, Chung-Nan Weng, Hsiu-Kang Chang
-
Publication number: 20080138419Abstract: The present invention provides a method for preparing an orally administrable formulation comprising a biologically active ingredient for controlled release in a neutral or basic environment, which comprises the steps of: (a) dispersing powder ethylcellulose with an average diameter from about 0.1 ?m to about 300 ?m in an aqueous solution to provide an aqueous dispersion, wherein the aqueous dispersion is substantially free of detergent; (b) mixing the biologically active ingredient and the aqueous dispersion obtained in step (a) to provide a mixture; and (c) spray-drying the mixture obtained in step (b) for about 10 seconds to about 2 minutes in a drying chamber at a chamber temperature of about 45° C. to about 100° C. to obtain the orally administrable formulation. An orally administrative formulation prepared by the method of the invention is also provided.Type: ApplicationFiled: February 20, 2007Publication date: June 12, 2008Inventors: Chao-Wei Liao, Peggy Lin, Chung-Nan Weng
-
Patent number: 7335361Abstract: The present invention mainly provides a fusion antigen specific for a target cell comprising a ligand moiety which is capable of reacting, recognizing or binding to the receptors on the target cell, a Pseudomonas exotoxin A translocation domain II, an antigenic moiety, and a carboxyl terminal moiety which permits combination of the fusion antigen to the endoplasmic reticulum (ER) membrane of the target cell. A method of immunizing an animal using the fusion antigen is also provided.Type: GrantFiled: June 9, 2003Date of Patent: February 26, 2008Assignee: Animal Technology Institute TaiwanInventors: Chao-Wei Liao, Chung-Nan Weng
-
Publication number: 20080008722Abstract: The present invention provides a PRRSV subunit vaccine comprising a fusion protein having neutralization titers evoked, PE-PQGAB-K3, which comprises a chimeric polypeptide containing N-terminal portions of PRRSV ORF5 and ORF6 structure proteins; a portion of Pseudomonas exotoxin A binding and translocation domain; and a carboxyl terminal domain containing KDEL-KDEL-KDEL(K3) sequence. Less inflammation of PE-PQGAB-K3 vaccine group in their lungs post being PRRSV-challenged indicates that PQGAB without an antigen-specific allergy effect. Importantly, PE-PQGAB-K3 vaccine presents a good protection against PRRSV infection than control groups in pig challenged experiment.Type: ApplicationFiled: July 5, 2006Publication date: January 10, 2008Applicant: Healthbanks Biotech Co., Ltd.Inventors: Hsiu-Kang Chang, Chao-Wei Liao
-
Publication number: 20050069899Abstract: The present invention provides a method of synthesizing a target polynucleotide that is efficiently expressed in a host-vector expression system, which uses a primer extension technique to constitute the target polynucleotide sequence. Preferably, the method is applied in a method for highly expressing a target heterogeneous polypeptide encoded by the target polynucleotide in a host.Type: ApplicationFiled: September 26, 2003Publication date: March 31, 2005Inventors: Chao-Wei Liao, Shin-Hung Lin, Chi-Min Chen, Chung-Nan Weng
-
Publication number: 20040247617Abstract: The present invention mainly provides a fusion antigen specific for a target cell comprising a ligand moiety which is capable of reacting, recognizing or binding to the receptors on the target cell, a Pseudomonas exotoxin A translocation domain II, an antigenic moiety, and a carboxyl terminal moiety which permits combination of the fusion antigen to the endoplasmic reticulum (ER) membrane of the target cell. A method of immunizing an animal using the fusion antigen is also provided.Type: ApplicationFiled: June 9, 2003Publication date: December 9, 2004Applicant: ANIMAL TECHNOLOGY INSTITUTE TAIWANInventors: Chao-Wei Liao, Chung-Nan Weng
-
Publication number: 20040208928Abstract: The present invention provides a method for preparing an orally administrable formulation comprising a biologically active ingredient for the controlled release in a neutral or basic environment, which method comprises the steps of: (a) dispersing powder ethylcellulose with an average diameter of from about 0.1 &mgr;m to about 300 &mgr;m in an aqueous dispersion to provide an enteric encapsulant; (b) mixing the biologically active ingredient and the enteric encapsulant obtained in step (a) to obtain a mixture; and (c) spray-drying the mixture obtained in step (b) for about 10 sec. to 15 sec. in a drying chamber at a chamber temperature of about 45° C. to about 80° C. to obtain an orally administrable formulation. The orally administrative formulation prepared by the method of the invention is also provided.Type: ApplicationFiled: April 15, 2003Publication date: October 21, 2004Applicant: ANIMAL TECHNOLOGY INSTITUTE TAIWANInventors: Chao-Wei Liao, Peggy Lin, Chung-Nan Weng
-
Patent number: 6159493Abstract: A formulation and a method for manufacturing an acne extraction patch. Water is added into polyvinyl alcohol and polyvinyl pyrrolidone to form an polymer solution. An adequate excipient is further added to form an optimal formulation. The formulation is coated directly onto the hydrophilic nonwovens or the nonwovens are placed over the release liner after coating the release liner with silicon coating. After the steps described above, the nonwovens are put into the dry oven for a two-step drying method at 55-90.degree. C., and 80-95.degree. C. A die-cut and package machine is used to cut an adequate patch. The patch is moistened with water and applied to the face or nose. The water solution of the formulation penetrates into the hair follicles or sebaceous glands. The lug of acne sticks to the polymer patch as the water evaporates. The acne is extracted from the hair follicle as the patch is removed.Type: GrantFiled: February 11, 1998Date of Patent: December 12, 2000Assignee: Caleb Pharmaceuticals, Inc.Inventors: Shu-Juan Chen, Chao-Wei Liao, Chien-Hsin D. Cheng
-
Patent number: 5962012Abstract: Scopolamine is a folksy cholinergic antagonist, and is used by parasympathetic nerves in autonomic nervous neurons as an anti-motion sickness drug or an anti-emesis drug. Since the human body most effectively absorbs this drug through the postauricular skin, the drug is administered by postauricular transdermal resorption patch. The penetrability of drug is increase by adding a dermal penetrative enhancer, because the penetration ability of patch-administered drugs is usually decreased by the penetrative blockade at dermal horny layers. The present invention discloses a penetration enhancer to increase dermal absorption and penetration of the cholinergic antagonist. The present invention finds that polyethylene and amide enhance penetration, about 2.2-2.8 fold. In accordance with the present invention, a penetration enhancer is added to the formulations of transdermal patch to increase the human body's absorption of scopolamine.Type: GrantFiled: February 11, 1998Date of Patent: October 5, 1999Assignee: Caleb Pharmaceuticals, Inc.Inventors: Wan-Yan Lin, Shu-Juan Chen, Chao-Wei Liao, Chien-Hsin D. Cheng